Just reported
From Resmed's results release of 29 de outubro de 2026; its quarterly report has since been filed.
Actual
US$ 1,41B
+5,9% y/y
-3,3% q/q
Guided
—
No guide given
Actual
US$ 2,92
+23% y/y
+11% q/q
Guided
—
No guide given
Actual
US$ 453M
+1,4% y/y
+1,0% q/q
Guided
—
No guide given
Full year 2027
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
As participações na receita são estimativas para quarter ended 2026-03-31, não números de um relatório oficial.
AirSense 11
A connected machine that delivers continuous or automatically adjusted air pressure to treat sleep apnea.
AirCurve 11
A bilevel breathing machine that provides different pressure levels for breathing in and out, for people needing more support or with complex breathing disorders.
Astral ventilators
Ventilators that provide breathing support, including for people receiving care at home.
AirTouch N30i, AirTouch F30i, and AirFit F40 masks
Masks that connect a person to a breathing machine during sleep; the named models include fabric and silicone designs.
myAir and AirView
Software for patients to engage with their sleep treatment and for providers to connect with and support patients.
Brightree and MEDIFOX DAN
Software products for residential care and home medical equipment providers.
Demonstrações financeiras completas →
ResMed makes devices that help people breathe during sleep and ventilators for people who need breathing support. It also sells masks and software for patients, medical equipment providers, and residential care providers. Its sleep products include machines that connect with patient and provider software.
Construído a partir dos próprios documentos de Resmed Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
US$ 239,53+0,2%fechamento 13 de nov.
Números até 30 de setembro de 2026, do 10-Q arquivado em 30 de outubro de 2026
ResMed sells breathing machines and masks for sleep apnea and other breathing disorders to patients through medical equipment providers.
The themes Resmed is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade B+
A faixa sob o preço mostra a nota em cada data, calculada só com os documentos já públicos naquele momento.
Mostrando 2 de 41 trimestres do histórico de notas de Resmed Inc.. Os outros 39 vão até outubro de 2016.